HydrOxychloRoqUine and Sorafenib in locally advanced or Metastatic Hepatocellular Carcinoma as First line therapy: a multi-center phase II trial.

Trial Profile

HydrOxychloRoqUine and Sorafenib in locally advanced or Metastatic Hepatocellular Carcinoma as First line therapy: a multi-center phase II trial.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Mar 2014

At a glance

  • Drugs Sorafenib (Primary) ; Hydroxychloroquine
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Acronyms HORUS
  • Most Recent Events

    • 10 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top